Healthcare - Biotechnology - NASDAQ - US
$ 1.1
0 %
$ 307 M
Market Cap
-1.39
P/E
BALANCE SHEET
750 M
ASSETS
95.1 M
LIABILITIES
655 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Lyell Immunopharma, Inc.
| Current Assets | 555 M |
| Cash & Short-Term Investments | 546 M |
| Receivables | 0 |
| Other Current Assets | 8.46 M |
| Non-Current Assets | 195 M |
| Long-Term Investments | 48.5 M |
| PP&E | 142 M |
| Other Non-Current Assets | 4.52 M |
| Current Liabilities | 34.5 M |
| Accounts Payable | 4.82 M |
| Short-Term Debt | 6.27 M |
| Other Current Liabilities | 23.4 M |
| Non-Current Liabilities | 60.6 M |
| Long-Term Debt | 56.9 M |
| Other Non-Current Liabilities | 3.66 M |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| ASSETS | |||||
| Cash & Cash Equivalents | 145.6 | 123.6 | 293.8 | 140.4 | 96.7 |
| Short Term Investments | 400.6 | 516.6 | 321.0 | 472.2 | 339.4 |
| Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 8.5 | 11.1 | 23.0 | 4.9 | 8.4 |
| Total Current Assets | 554.7 | 651.3 | 626.3 | 617.5 | 440.3 |
| PP&E | 142.3 | 166.3 | 166.6 | 124.1 | 43.7 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 48.5 | 115.0 | 330.5 | 163.4 | 69.0 |
| Other Long Term Assets | 4.5 | 5.0 | 3.9 | 3.2 | 2.7 |
| Other Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 750.0 | 937.6 | 1 127.4 | 908.3 | 555.6 |
| LIABILITIES | |||||
| Accounts Payable | 4.8 | 3.9 | 3.2 | 9.4 | 2.8 |
| Short Term Debt | 6.3 | 4.5 | 1.2 | 3.6 | 0.3 |
| Other Current Liabilities | 23.4 | 28.6 | 37.4 | 30.2 | 14.3 |
| Total Current Liabilities | 34.5 | 37.0 | 46.7 | 49.3 | 22.0 |
| Long Term Debt | 56.9 | 126.3 | 133.3 | 51.0 | 27.1 |
| Deferred Tax Income | 0 | 0 | 0 | 0 | (98.4) |
| Other Liabilities | 3.7 | (59.1) | (62.1) | 0.5 | 0 |
| Total Liabilities | 95.1 | 104.3 | 197.6 | 189.8 | 147.6 |
| EQUITY | |||||
| Common Stock | 25 K | 25 K | 24 K | 2 K | 1 K |
| Retained Earnings | (1 002.1) | (767.5) | (584.4) | (334.1) | (129.7) |
| Other Accumulative Comprehensive Income/Loss | 94 K | (7.6) | (1.6) | 0.3 | 0.5 |
| Total Equity | 655.0 | 833.3 | 929.8 | 718.4 | 408.1 |
| Total Liabilities and Equity | 750.0 | 937.6 | 1 127.4 | 908.3 | 555.6 |
| SHARES OUTSTANDING | |||||
| Common Shares Outstanding | 251.0 | 247.1 | 242.7 | 246.6 | 246.6 |